PE20211591A1 - Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiranosidasa - Google Patents
Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiranosidasaInfo
- Publication number
- PE20211591A1 PE20211591A1 PE2021000333A PE2021000333A PE20211591A1 PE 20211591 A1 PE20211591 A1 PE 20211591A1 PE 2021000333 A PE2021000333 A PE 2021000333A PE 2021000333 A PE2021000333 A PE 2021000333A PE 20211591 A1 PE20211591 A1 PE 20211591A1
- Authority
- PE
- Peru
- Prior art keywords
- glucopyranosidase
- acetamido
- deoxy
- glycoprotein
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 2
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733484P | 2018-09-19 | 2018-09-19 | |
| US201862750000P | 2018-10-24 | 2018-10-24 | |
| PCT/US2019/051661 WO2020061150A1 (en) | 2018-09-19 | 2019-09-18 | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211591A1 true PE20211591A1 (es) | 2021-08-18 |
Family
ID=68073263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000333A PE20211591A1 (es) | 2018-09-19 | 2019-09-18 | Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiranosidasa |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US12180205B2 (https=) |
| EP (1) | EP3853226A1 (https=) |
| JP (2) | JP7606960B2 (https=) |
| KR (1) | KR20210060513A (https=) |
| CN (2) | CN113166137B (https=) |
| AU (1) | AU2019344922B2 (https=) |
| BR (1) | BR112021004739A2 (https=) |
| CA (1) | CA3113009A1 (https=) |
| CL (1) | CL2021000646A1 (https=) |
| CO (1) | CO2021004873A2 (https=) |
| CR (1) | CR20210181A (https=) |
| IL (2) | IL315564A (https=) |
| JO (1) | JOP20210036A1 (https=) |
| MA (1) | MA53648A (https=) |
| MX (1) | MX2021003232A (https=) |
| PE (1) | PE20211591A1 (https=) |
| PH (1) | PH12021550439A1 (https=) |
| SG (1) | SG11202102379XA (https=) |
| TW (1) | TWI863926B (https=) |
| UA (1) | UA130690C2 (https=) |
| UY (1) | UY38376A (https=) |
| WO (1) | WO2020061150A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12180205B2 (en) * | 2018-09-19 | 2024-12-31 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
| EP3643711A1 (en) | 2018-10-24 | 2020-04-29 | Bayer Animal Health GmbH | New anthelmintic compounds |
| WO2022031701A1 (en) * | 2020-08-03 | 2022-02-10 | Biogen Ma Inc. | Crystaline forms of an o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitor |
| KR102533471B1 (ko) * | 2020-11-23 | 2023-05-19 | (주) 메디프론디비티 | O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도 |
| WO2025184490A1 (en) | 2024-03-01 | 2025-09-04 | Biogen Ma Inc. | N-[4-fluor-5-[[(2s, 4 r)-4-[(6-methoxy-4-pyrimidinyl)oxy]- 2-methyl-1-pyrrolidinyl] methyl ]-2-thiazolyl]acetamid for use in the treatment of alzheimer disease |
| US12612396B1 (en) | 2024-11-20 | 2026-04-28 | Dewpoint Therapeutics, Inc. | Modulators of beta catenin and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| JP2004520347A (ja) | 2001-01-15 | 2004-07-08 | グラクソ グループ リミテッド | Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体 |
| BRPI0515500A (pt) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados piridazina para inibição de estearoil-coa-desaturase |
| SG172352A1 (en) | 2008-12-23 | 2011-07-28 | Abbott Lab | Anti-viral compounds |
| JP2013526546A (ja) | 2010-05-13 | 2013-06-24 | アムジエン・インコーポレーテツド | Ｐｄｅ１０阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物 |
| EP2780014A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| US9051269B2 (en) | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013078320A1 (en) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP5989805B2 (ja) | 2012-02-10 | 2016-09-07 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | メチル基変更酵素の調節物質、組成物及びその使用 |
| WO2013170072A2 (en) | 2012-05-09 | 2013-11-14 | Neurop, Inc. | Compounds for the treatment of neurological disorders |
| WO2014067003A1 (en) | 2012-10-31 | 2014-05-08 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| MA38341B1 (fr) | 2013-02-11 | 2018-11-30 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| PT2970272T (pt) | 2013-03-14 | 2019-06-05 | Merck Patent Gmbh | Inibidores de glicosidase |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| KR20160100408A (ko) | 2014-01-06 | 2016-08-23 | 리젠 파마슈티컬스 소시에떼 아노님 | 신규한 글루타미나제 저해제 |
| CN105753814A (zh) | 2015-01-01 | 2016-07-13 | 成都贝斯凯瑞生物科技有限公司 | 取代氮杂环衍生物及其应用 |
| US20190359609A1 (en) * | 2016-12-16 | 2019-11-28 | Janssen Pharmaceutica Nv | Bicyclic oga inhibitor compounds |
| EP3555087A1 (en) * | 2016-12-16 | 2019-10-23 | Janssen Pharmaceutica NV | Monocyclic oga inhibitor compounds |
| TWI654978B (zh) | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5－甲基－1,2,4－二唑－3－基化合物 |
| JP7453916B2 (ja) * | 2018-03-14 | 2024-03-21 | バイオジェン・エムエイ・インコーポレイテッド | Ｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グリコピラノシダーゼ阻害剤 |
| US11459324B2 (en) | 2018-03-14 | 2022-10-04 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors |
| CA3102903A1 (en) | 2018-06-20 | 2019-12-26 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| US12180205B2 (en) | 2018-09-19 | 2024-12-31 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
-
2019
- 2019-09-18 US US17/276,502 patent/US12180205B2/en active Active
- 2019-09-18 JP JP2021515045A patent/JP7606960B2/ja active Active
- 2019-09-18 KR KR1020217010451A patent/KR20210060513A/ko not_active Ceased
- 2019-09-18 AU AU2019344922A patent/AU2019344922B2/en active Active
- 2019-09-18 IL IL315564A patent/IL315564A/en unknown
- 2019-09-18 JO JOP/2021/0036A patent/JOP20210036A1/ar unknown
- 2019-09-18 TW TW108133538A patent/TWI863926B/zh active
- 2019-09-18 EP EP19779339.1A patent/EP3853226A1/en active Pending
- 2019-09-18 MA MA053648A patent/MA53648A/fr unknown
- 2019-09-18 CN CN201980060829.1A patent/CN113166137B/zh active Active
- 2019-09-18 SG SG11202102379XA patent/SG11202102379XA/en unknown
- 2019-09-18 WO PCT/US2019/051661 patent/WO2020061150A1/en not_active Ceased
- 2019-09-18 IL IL281514A patent/IL281514B2/en unknown
- 2019-09-18 PE PE2021000333A patent/PE20211591A1/es unknown
- 2019-09-18 CA CA3113009A patent/CA3113009A1/en active Pending
- 2019-09-18 CN CN202411009108.7A patent/CN119219621A/zh active Pending
- 2019-09-18 CR CR20210181A patent/CR20210181A/es unknown
- 2019-09-18 UY UY0001038376A patent/UY38376A/es active IP Right Grant
- 2019-09-18 UA UAA202101992A patent/UA130690C2/uk unknown
- 2019-09-18 MX MX2021003232A patent/MX2021003232A/es unknown
- 2019-09-18 BR BR112021004739-5A patent/BR112021004739A2/pt unknown
-
2021
- 2021-03-02 PH PH12021550439A patent/PH12021550439A1/en unknown
- 2021-03-16 CL CL2021000646A patent/CL2021000646A1/es unknown
- 2021-04-16 CO CONC2021/0004873A patent/CO2021004873A2/es unknown
-
2024
- 2024-05-24 US US18/673,619 patent/US12275728B2/en active Active
- 2024-09-27 JP JP2024168726A patent/JP2025011144A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202102379XA (en) | 2021-04-29 |
| US20240308995A1 (en) | 2024-09-19 |
| IL281514B2 (en) | 2025-02-01 |
| IL281514A (en) | 2021-04-29 |
| JP2022500472A (ja) | 2022-01-04 |
| UY38376A (es) | 2020-04-30 |
| AU2019344922A1 (en) | 2021-03-25 |
| CO2021004873A2 (es) | 2021-07-30 |
| BR112021004739A2 (pt) | 2021-06-01 |
| CN119219621A (zh) | 2024-12-31 |
| JP2025011144A (ja) | 2025-01-23 |
| TWI863926B (zh) | 2024-12-01 |
| US12275728B2 (en) | 2025-04-15 |
| UA130690C2 (uk) | 2026-04-22 |
| PH12021550439A1 (en) | 2021-11-29 |
| CN113166137B (zh) | 2024-08-16 |
| CN113166137A (zh) | 2021-07-23 |
| WO2020061150A1 (en) | 2020-03-26 |
| TW202031651A (zh) | 2020-09-01 |
| EP3853226A1 (en) | 2021-07-28 |
| JOP20210036A1 (ar) | 2021-02-25 |
| CL2021000646A1 (es) | 2021-09-03 |
| US20220041586A1 (en) | 2022-02-10 |
| IL281514B1 (en) | 2024-10-01 |
| AU2019344922B2 (en) | 2025-02-06 |
| IL315564A (en) | 2024-11-01 |
| CA3113009A1 (en) | 2020-03-26 |
| CR20210181A (es) | 2021-07-01 |
| US12180205B2 (en) | 2024-12-31 |
| JP7606960B2 (ja) | 2024-12-26 |
| KR20210060513A (ko) | 2021-05-26 |
| MA53648A (fr) | 2021-07-28 |
| MX2021003232A (es) | 2021-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211591A1 (es) | Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiranosidasa | |
| PE20221628A1 (es) | Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos | |
| PE20210128A1 (es) | Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas | |
| PE20151748A1 (es) | Inhibidores de bace1 | |
| PE20201185A1 (es) | Inhibidores de la oxacina monoacilglicerol lipasa (magl) | |
| PE20141681A1 (es) | Inhibidores de btk | |
| PE20210657A1 (es) | Compuestos | |
| PE20180355A1 (es) | Desacetoxitubulisina h y analogos de esta | |
| PE20231746A1 (es) | Compuestos de union a cereblon, composiciones de estos y metodos de tratamiento con estos | |
| PE20161427A1 (es) | Inhibidores heteroarilo de syk | |
| PE20180160A1 (es) | Sulfonilureas y compuestos relacionados y uso de estos | |
| CL2013002299A1 (es) | Compuestos derivados de heterociclos, inhibidores de la replicacion del virus de la hepatitis c; composicion farmaceutica que los comprende; util en el tratamiento de una infeccion por vhc. (divisional solicitud 689-2011). | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| PE20181352A1 (es) | Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias | |
| CL2012001366A1 (es) | Compuestos derivados de carboxamida n-((2-morfolino-5-ariltiazol-4-il)metil), moduladores de receptores nicotinicos alfa 7; composicion farmaceutica; proceso para prepararla; combinacion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, demencia, esquizofrenia, enfermedad de parkinson, entre otras. | |
| PE20170004A1 (es) | Inhibidores de biaril cinasa | |
| PE20091972A1 (es) | Compuestos heterociclicos como inhibidores del factor ixa | |
| UA122498C2 (uk) | Біциклічні похідні, спосіб їх отримання та фармацевтичні композиції, що їх містять | |
| PE20091734A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| PE20130009A1 (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana | |
| CR8249A (es) | Forma cristalina gamma del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que lo contienen | |
| PE20140849A1 (es) | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida | |
| SV2011003855A (es) | Heteroarilos sustituidos |